Linked Life Data

6749399

Source:http://linkedlifedata.com/resource/pubmed/id/6749399

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1982-12-2
pubmed:abstractText
Insufficient information is available about the effectiveness of high-dose intravenous corticosteroid treatment in non-renal SLE to determine whether it provides better management of the disease. Issues of steroid preparation, dose and frequency have not been addressed. Significant short-term complications appear to be minimal; the question of long-term effects on avascular necrosis may not be answerable since most patients also receive oral corticosteroids at some time during their course. No large randomized controlled trial of pulse IV-MP in lupus nephritis is available. Ideally, such a trial would include randomization with stratification according to important prognostic variables. Previous studies of other agents have been hampered by lack of agreement about both the identification of relevant prognostic variables and the selection of 'significant' measures of outcome. The observation that patients with recent deterioration in glomerular filtration rate are more likely to improve after IV-MP may form the basis for stratification in a controlled trial of the comparative efficacy of IV-MP and other forms of treatment. However, lack of improvement in glomerular filtration rate among patients without recent deterioration in function may reflect the inadequacy of our outcome measures rather than a true lack of beneficial effect for the patient.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0307-742X
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
261-78
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Pulse methylprednisolone in SLE.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't